The CMO of La Jolla Pharma (LJPC) is Buying Shares


Yesterday, the CMO of La Jolla Pharma (LJPC), Lakhmir Chawla, bought shares of LJPC for $16.69K.

Following this transaction Lakhmir Chawla’s holding in the company was increased by 5084.75% to a total of $31.76K. In addition to Lakhmir Chawla, 5 other LJPC executives reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Based on La Jolla Pharma’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $3.47 million and GAAP net loss of $50.75 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $38.55 million. Currently, La Jolla Pharma has an average volume of 741.4K.

Based on 5 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $18.00, reflecting a 198.0% upside. Three different firms, including Cowen & Co. and SunTrust Robinson, currently also have a Buy rating on the stock.

In the last 30 days, insiders have sold $11.72M worth of LJPC shares and purchased $7.04M worth of LJPC shares. The insider sentiment on La Jolla Pharma has been positive according to 50 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb.

Read More on LJPC:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts